Abstract: The present invention relates to an optically active axially chiral ?-allenic alcohol, a synthesis method and use thereof. The invention relates to a method of preparing a highly optically active chiral ?-allenic alcohol by using propargyl alcohol, aldehyde and chiral ?,?-diphenyl-L-prolinol under the protection of tert-butyldimethylsilyl with an accelerant zinc bromide. The axially chiral ?-allenic alcohol has the structural formula (I). The method of the present invention has the following advantages: the synthesis route is short, operations are simple, raw materials are readily available, separation and purification are convenient, the substrate has high universality, the total yield is high, and enantioselectivity and diastereoselectivity are high.

Abstract: Hsp90 inhibitors having are provided having the formula: (I) with a 2?,4?,5?-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4? and 5? positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO2-alkyl, COO-alkyl, KH2, OH, CN, SO2X5, NO2, NO, C?SR2NSO2X5, C?OR2, where X5 is F, NH2, alkyl or H, and R2 is alkyl, NH2, NH-alkyl or O-alkyl, C1 to C6 alkyl or alkoxy; or wherein X1 has the formula —O—(CH2)n—O—, wherein n is an integer from 0 to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5?-position and the other at the 4?-position of the aryl ring. The compounds are useful in cancer therapy and as radioimaging ligands.

Abstract: The present invention relates to a process for the preparation of canagliflozin and intermediates thereof.

Abstract: Provided is a process of conducting a Baeyer-Villiger oxidation which comprises contacting a ketone and an oxidant in the presence of an Sn-DZ-1 catalyst to thereby oxidize the ketone to an ester. The Sn-DZ-1 catalyst comprises Sn heteroatoms on the external surface of the zeolitic material lattice framework, and B heteroatoms, or silanols created from boron hydrolysis, throughout the remainder of the lattice framework.

Abstract: Provided are catalysts suitable for the production of tetrahydrofuran from 1,4-butanediol. Also provided are methods of use of these catalyst, as well as catalyst systems. The catalysts described herein contain only Lewis acidity, but not Brønsted acidity, which results in decreased production of ether byproducts.

Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

Abstract: Macrocyclic compounds having the structure of Formula (A), or pharmaceutically acceptable salts thereof, are provided, wherein R1, R2, Z1, Z2, v, T, L, R3, R4 and R5 are defined herein. Also provided are pharmaceutical compositions comprising the macrocyclic compound and methods for treating cancer in a patient comprising administering to the patient the macrocyclic compound.

Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

Abstract: Provided are catalysts suitable for the production of tetrahydrofuran from 1,4-butanediol. Also provided are methods of use of these catalyst, as well as catalyst systems. The catalysts described herein contain only Lewis acidity, but not Broønsted acidity, which results in decreased production of ether byproducts.

Abstract: The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.

Abstract: 2,5-Furandicarboxylic acid and methyl acetate are prepared in a continuous process by introducing a 5-methoxymethylfurfural-containing feedstock, an oxygen-containing gas, an oxidation catalyst and an acetic acid-containing solvent into a reactor; allowing 5-methoxymethylfurfural to react with oxygen and acetic acid in the presence of the oxidation catalyst to yield 2,5-furandicarboxylic acid as main product and methyl acetate; withdrawing 2,5-furandicarboxylic acid-containing product from the reactor and recovering 2,5-furandicarboxylic acid product; and withdrawing a vaporous stream containing methyl acetate from the reactor.

Abstract: The nonionic surfactant of the present invention has a structure represented by formula (1): wherein each of R1 and R4 is a hydrogen atom or an alkyl group; each of R2, R3, R5, and R6 is a hydrocarbon group that may contain an ether bond; R2 and R3 may be bonded together to form a cyclic structure, and R5 and R6 may be bonded together to form a cyclic structure; AO represents an oxyalkylene group or oxyalkylene groups that may be the same or different; and n is a number of 1 to 1000 and represents an average addition molar number of the oxyalkylene group or oxyalkylene groups.

Abstract: The present disclosure provides methods to produce substituted furans (e.g., halomethylfurfural, hydroxymethylfurfural, and furfural), by acid-catalyzed conversion of biomass using a gaseous acid in a multiphase reactor, such as a fluidized bed reactor.

Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.

Abstract: The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.

Abstract: A technological method for synthesizing optically pure L-/D-lactide by using a biogenic guanidine catalysis method. The method of the present invention comprises: by using biogenic guanidine creatinine (CR) as a catalyst and L-/D-lactic acid (90% of mass content) as a raw material, synthesizing optically pure L-/D-lactide by using a reactive reduced pressure distillation catalysis method.

Abstract: A novel amine derivative expressed by general formula (1) (in the formula: G1, G2, and G3 are the same or different and represent CH or a nitrogen atom; R1 represents a chlorine atom, an optionally-substituted C3-8 cycloalkyl group, or the like; R2 represents —COOR5 (in the formula, R5 represents a hydrogen atom or a carboxyl protective group), or the like; R3 represents a hydrogen atom, or the like; and R4 represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.

Abstract: A method of preparing naringenin nanoparticles comprises dissolving naringenin in an organic solvent to form a solution; adding the solution to boiling water under ultrasonic conditions to form a mixture; and stirring the mixture to obtain the naringenin nanoparticles. The organic solvent can be at least one of methanol, ethanol, dichloromethane and chloroform. Ultrasonic conditions can include applying ultrasonic energy at a frequency of 30-60 kHz and a power of 100 watts for about 20-30 minutes to the mixture.

Abstract: The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.

Abstract: The present invention suggests a 2-oxo-1,3-dioxolane-4-carboxamide of formula (I), wherein R is an n-valent radical, n is an integer from 2 to 4, preferably from 2 to 3, and x is an integer from 1 to n?1. The invention furthermore suggests a process for the preparation of the 2-oxo-1,3-dioxolane-4-carboxamide of formula (I) from 2-oxo-1,3-dioxolane-4-carboxylic acid of formula (II) with a polyisocyanate of the formula R(NCO)n, where R and n have the meanings given, the use of the 2-oxo-1,3-dioxolane-4-carboxamide of formula (I) for the preparation of a 2-oxo-1,3-dioxolane-4-carboxamide-substituted prepolymer, and the 2-oxo-1,3-dioxolane-4-carboxamide-substituted prepolymer thus obtainable.